Medtech Investment Outlook: In Health Care You Don’t Become A Unicorn Overnight
Executive Summary
The pandemic has shaken up investor priorities and changed the outlook for health care start-ups – or has it? Nooman Haque managing director, life sciences and healthcare at Silicon Valley Bank, gives his view of what has changed over the past year, and looks at future trends.
You may also be interested in...
Pandemic Perspectives: Riding The Waves Of Asia’s Healthtech Innovation Explosion
One year on, we’ve seen how the coronavirus prompted entrepreneurial instincts to surface in the medtech and healthtech sectors. Asia healthtech investor specialist HealthXCapital tells Medtech Insight about the changes that are likely to stick as in an industry that has seen the value of rapid responsiveness to acute need.
GDP And UDI On List Of Regulatory Changes Under Taiwan Medical Device Act
Taiwan’s Medical Device Act was enforced on 1 May, bringing changes to good distribution practice and laying the foundation for UDI regulations.
Royal Philips: From Medtech Supplier To Health Care Solutions Partner
Health care delivery has been transformed over the past decade, and so has Royal Philips, whose CEO Frans van Houten explains why both were necessary, and the extra impetus for system-wide change following the COVID-19 pandemic.